Literature DB >> 24569305

Prospective validation of a risk prediction model for severe sepsis in children with cancer and high-risk febrile neutropenia.

María E Santolaya1, Ana M Alvarez, Carmen L Avilés, Ana Becker, Marcela Venegas, Miguel O'Ryan, Carmen Salgado, Santiago Topelberg, Juan Tordecilla, Mónica Varas, Milena Villarroel, Tamara Viviani, Marcela Zubieta, Verónica de la Maza, Alejandra Vergara, Mauricio J Farfán, Juan P Torres.   

Abstract

BACKGROUND: We previously created a risk prediction model for severe sepsis not clinically apparent during the first 24 hours of hospitalization in children with high-risk febrile neutropenia (HRFN), which identified 3 variables, age ≥ 12 years, serum C-reactive protein (CRP) ≥ 90 mg/L and interleukin-8 ≥ 300 pg/mL, evaluated at the time of admission and at 24 hours of hospitalization. The combination of these 3 variables identified a risk for severe sepsis ranging from 8% to 73% with a relative risk of 3.15 (95% confidence interval: 1.1-9.06). The aim of this study was to validate prospectively our risk prediction model for severe sepsis in a new cohort of children with cancer and HRFN.
METHODS: Predictors of severe sepsis identified in our previous model (age, CRP and interleukin-8) were evaluated at admission and at 24 hours of hospitalization in a new cohort of children with HRFN between April 2009 and July 2011. Diagnosis of severe sepsis, not clinically apparent during the first 24 hours of hospitalization, was made after discharge by a blind evaluator.
RESULTS: A total of 447 HRFN episodes were studied, of which 76 (17%) had a diagnosis of severe sepsis. The combination of age ≥ 12 years, CRP ≥ 90 mg/L and interleukin-8 ≥ 300 pg/mL at admission and/or at 24 hours in the new cohort identified a risk for severe sepsis ranging from 7% to 46% with an RR of 6.7 (95% CI: 2.3-19.5).
CONCLUSIONS: We validated a risk prediction model for severe sepsis applicable to children with HRFN episodes within the first 24 hours of admission. We propose to incorporate this model in the initial patient assessment to offer a more selective management for children at risk for severe sepsis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24569305     DOI: 10.1097/01.inf.0000436128.49972.16

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Development and validation of a prediction model for diagnosing blood stream infections in febrile, non-neutropenic children with cancer.

Authors:  Adam J Esbenshade; M Cecilia Di Pentima; Zhiguo Zhao; Ayumi Shintani; Jennifer C Esbenshade; Monique E Simpson; Kathleen C Montgomery; Robert B Lindell; Haerin Lee; Ato Wallace; Kelly L Garcia; Karel G M Moons; Debra L Friedman
Journal:  Pediatr Blood Cancer       Date:  2014-10-18       Impact factor: 3.167

Review 2.  Use of biomarkers in pediatric sepsis: literature review.

Authors:  Vanessa Soares Lanziotti; Pedro Póvoa; Márcio Soares; José Roberto Lapa E Silva; Arnaldo Prata Barbosa; Jorge Ibrain Figueira Salluh
Journal:  Rev Bras Ter Intensiva       Date:  2016 Oct-Dec

3.  Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial.

Authors:  M E Santolaya; A M Alvarez; M Acuña; C L Avilés; C Salgado; J Tordecilla; M Varas; M Venegas; M Villarroel; M Zubieta; A Toso; A Bataszew; M J Farfán; V de la Maza; A Vergara; R Valenzuela; J P Torres
Journal:  Clin Microbiol Infect       Date:  2016-11-14       Impact factor: 8.067

4.  Clinical decision rules for infectious risk stratification of children with febrile neutropenia: Are we looking for the Yeti?

Authors:  Elio Castagnola; Carlo Dufour
Journal:  EClinicalMedicine       Date:  2020-01-25

5.  Comparison of epidemiological, clinical and microbiological characteristics of bloodstream infection in children with solid tumours and haematological malignancies.

Authors:  M M Garrido; R Q Garrido; T N Cunha; S Ehrlich; I S Martins
Journal:  Epidemiol Infect       Date:  2019-11-08       Impact factor: 2.451

6.  Biomarkers for Diagnosing Febrile Illness in Immunocompromised Children: A Systematic Review of the Literature.

Authors:  Fabian J S van der Velden; Andrew R Gennery; Marieke Emonts
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

7.  Use of biomarkers in the management of febrile neutropenia episodes in children with cancer.

Authors:  Benigna Maria de Oliveira
Journal:  Rev Bras Hematol Hemoter       Date:  2015-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.